Company · celularity-incorporated-2ca2ed0e
Celularity Incorporated
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. Celularity Incorporated. Companies, record celularity-incorporated-2ca2ed0e. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/celularity-incorporated-2ca2ed0e
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- Celularity Incorporated
- Trials
- 17
- As lead sponsor
- 17
- As collaborator
- 0
- Recruiting
- 0
- Active, recruiting or not
- 0
- Completed
- 5
- Stopped early, withdrawn or suspended
- 11
- Posted results
- 4
- Trials by phase
- Phase 1 11, Phase 2 9
- Drugs its trials test
- 6
- Comparisons calculated in its trials
- 0
- First trial registered
- 2010-07-01
- Last update
- 2026-07-07
Source ClinicalTrials.gov
Pipeline6
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| TANIRALEUCEL | Phase 1/2 | 6 | 6 | 0 | https://conductscience.org/library/drugs/CHEMBL5314619 | Open Targets | ||
| PEMBROLIZUMAB | Phase 1/2 | 1 | 1 | 0 | PDCD1 | Programmed cell death protein 1 inhibitor | https://conductscience.org/library/drugs/CHEMBL3137343 | Open Targets |
| TRASTUZUMAB | Phase 1/2 | 1 | 1 | 0 | ERBB2 | Receptor protein-tyrosine kinase erbB-2 inhibitor | https://conductscience.org/library/drugs/CHEMBL1201585 | Open Targets |
| ALDESLEUKIN | Phase 1 | 1 | 1 | 0 | IL2RA, IL2RB, IL2RG | Interleukin-2 receptor agonist | https://conductscience.org/library/drugs/CHEMBL1201438 | Open Targets |
| CENPLACEL-L | Phase 1 | 1 | 1 | 0 | https://conductscience.org/library/drugs/CHEMBL2107867 | Open Targets | ||
| TROCULEUCEL | Phase 1 | 1 | 1 | 0 | https://conductscience.org/library/drugs/CHEMBL5314888 | Open Targets |
Trials17
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05218408 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | Lead sponsor | Phase 1/2 | Withdrawn | Interventional | 0 | 2021-09 | TANIRALEUCEL | https://conductscience.org/library/trials/NCT05218408 | ClinicalTrials.gov | |
| NCT05207722 | CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | Lead sponsor | Phase 1/2 | Terminated | Interventional | 1 | 2022-04-14 | PEMBROLIZUMAB, TRASTUZUMAB | https://conductscience.org/library/trials/NCT05207722 | ClinicalTrials.gov | |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | Lead sponsor | Phase 1 | Terminated | Interventional | 3 | 2020-10-01 | TROCULEUCEL | https://conductscience.org/library/trials/NCT04489420 | ClinicalTrials.gov | |
| NCT04365101 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | Lead sponsor | Phase 1/2 | Terminated | Interventional | 7 | 2020-09-02 | 2026-06-01 | TANIRALEUCEL | https://conductscience.org/library/trials/NCT04365101 | ClinicalTrials.gov |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML | Lead sponsor | Phase 1 | Terminated | Interventional | 27 | 2020-03-12 | TANIRALEUCEL | https://conductscience.org/library/trials/NCT04310592 | ClinicalTrials.gov | |
| NCT04309084 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | Lead sponsor | Phase 1 | Unknown status | Interventional | 29 | 2020-05-12 | TANIRALEUCEL | https://conductscience.org/library/trials/NCT04309084 | ClinicalTrials.gov | |
| NCT02955550 | A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) | Lead sponsor | Phase 1 | Completed | Interventional | 15 | 2017-01-05 | ALDESLEUKIN, TANIRALEUCEL | https://conductscience.org/library/trials/NCT02955550 | ClinicalTrials.gov | |
| NCT02781467 | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) | Lead sponsor | Phase 1 | Terminated | Interventional | 10 | 2016-07-11 | TANIRALEUCEL | https://conductscience.org/library/trials/NCT02781467 | ClinicalTrials.gov | |
| NCT02552277 | A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy | Lead sponsor | Phase 2 | Completed | Interventional | 26 | 2015-10-27 | https://conductscience.org/library/trials/NCT02552277 | ClinicalTrials.gov | ||
| NCT02460081 | Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease | Lead sponsor | Phase 2 | Withdrawn | Interventional | 0 | 2015-06 | https://conductscience.org/library/trials/NCT02460081 | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsConditions67
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Analgesics | 4 |
| Physiological Effects of Drugs | 4 |
| Analgesics, Non-narcotic | 3 |
| Anti-infective Agents | 3 |
| Antiviral Agents | 3 |
| Immunologic Factors | 3 |
| Peripheral Arterial Disease | 3 |
| Peripheral Nervous System Agents | 3 |
| Antimetabolites, Antineoplastic | 2 |
| Astrocytoma, Grade IV | 2 |
1 to 10 of 67Source ClinicalTrials.gov
See all 67 conditionsPartners3
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| Celgene Corporation | Industry | 3 | https://conductscience.org/library/companies/celgene-corporation-caa7f5bb | ClinicalTrials.gov |
| Access to Advanced Health Institute (AAHI) | Other | 1 | ClinicalTrials.gov | |
| California Institute for Regenerative Medicine (CIRM) | Other | 1 | ClinicalTrials.gov |
Data dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/celularity-incorporated-2ca2ed0e
GET https://conductscience.org/api/companies/v1/celularity-incorporated-2ca2ed0e/conditions?page=2